Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36.

Diabetes mellitus has been associated with platelet hyperreactivity, which plays a central role in the hyperglycemia-related prothrombotic phenotype. The mechanisms responsible for this phenomenon are not established. In the present study, we investigated the role of CD36, a class-B scavenger receptor, in this process. Using both in vitro and in vivo mouse models, we demonstrated direct and specific interactions of platelet CD36 with advanced glycation end products (AGEs) generated under hyperglycemic conditions. AGEs bound to platelet CD36 in a specific and dose-dependent manner, and binding was inhibited by the high-affinity CD36 ligand NO(2)LDL. Cd36-null platelets did not bind AGE. Using diet- and drug-induced mouse models of diabetes, we have shown that cd36-null mice had a delayed time to the formation of occlusive thrombi compared with wild-type (WT) in a FeCl(3)-induced carotid artery injury model. Cd36-null mice had a similar level of hyperglycemia and a similar level of plasma AGEs compared with WT mice under this condition, but WT mice had more AGEs incorporated into thrombi. Mechanistic studies revealed that CD36-dependent JNK2 activation is involved in this prothrombotic pathway. Therefore, the results of the present study couple vascular complications in diabetes mellitus with AGE-CD36-mediated platelet signaling and hyperreactivity.

[1]  J. Barnard,et al.  Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms. , 2011, Blood.

[2]  T. Barbui,et al.  Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. , 2011, Blood.

[3]  J. Major,et al.  Vav guanine nucleotide exchange factors link hyperlipidemia and a prothrombotic state. , 2011, Blood.

[4]  D. Angiolillo,et al.  Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome , 2011, Circulation.

[5]  O. Garraud,et al.  Platelet Toll-like receptor expression: the link between "danger" ligands and inflammation. , 2010, Inflammation & allergy drug targets.

[6]  S. Reddy,et al.  CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs. , 2010, The Journal of clinical investigation.

[7]  Ferdinando Giacco,et al.  Oxidative stress and diabetic complications. , 2010, Circulation research.

[8]  D. Angiolillo,et al.  Review article: Platelet abnormalities in diabetes mellitus , 2010, Diabetes & vascular disease research.

[9]  Yuan Liu,et al.  Pyridoxine improves platelet nitric oxide synthase dysfunction induced by advanced glycation end products in vitro. , 2010, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[10]  B. Burlando,et al.  Hmgb1 Promotes Wound Healing of 3T3 Mouse Fibroblasts via Rage-Dependent ERK1/2 Activation , 2010, Cell Biochemistry and Biophysics.

[11]  R. Ramasamy,et al.  The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. , 2010, Circulation research.

[12]  S. Yamagishi,et al.  Pigment epithelium‐derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs) , 2009, Diabetes/metabolism research and reviews.

[13]  R. Silverstein,et al.  A Specific CD36-Dependent Signaling Pathway Is Required for Platelet Activation by Oxidized Low-Density Lipoprotein , 2008, Circulation research.

[14]  K. McCrae,et al.  Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. , 2008, The Journal of clinical investigation.

[15]  G. Davı̀,et al.  Platelet activation and atherothrombosis. , 2007, The New England journal of medicine.

[16]  Y. Huang,et al.  17β‐OESTRADIOL PARTIALLY ATTENUATES THE INHIBITION OF NITRIC OXIDE SYNTHASE‐3 BY ADVANCED GLYCATION END‐PRODUCTS IN HUMAN PLATELETS , 2007, Clinical and experimental pharmacology & physiology.

[17]  S. Hazen,et al.  Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype , 2007, Nature Medicine.

[18]  S. Horiuchi,et al.  Pathological Roles of Advanced Glycation End Product Receptors SR‐A and CD36 , 2005, Annals of the New York Academy of Sciences.

[19]  B. Sobel,et al.  Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. , 2003, The American journal of cardiology.

[20]  J. Beckman,et al.  Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I , 2003, Circulation.

[21]  Yijun Deng,et al.  Identification of a Novel Family of Oxidized Phospholipids That Serve as Ligands for the Macrophage Scavenger Receptor CD36* , 2002, The Journal of Biological Chemistry.

[22]  M. Namba,et al.  Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus. , 2002, Thrombosis research.

[23]  R. Eckel,et al.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. , 2002, Circulation.

[24]  L. Mazzanti,et al.  Glycated low density lipoproteins modify platelet properties: a compositional and functional study. , 2002, The Journal of clinical endocrinology and metabolism.

[25]  H. Vlassara.  The AGE‐receptor in the pathogenesis of diabetic complications , 2001, Diabetes/metabolism research and reviews.

[26]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[27]  Hiroyuki Arai,et al.  CD36, a Member of the Class B Scavenger Receptor Family, as a Receptor for Advanced Glycation End Products* , 2001, The Journal of Biological Chemistry.

[28]  A. Pfeiffer,et al.  Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro , 2001, Diabetologia.

[29]  A. Schmidt,et al.  RAGE: A New Target for the Prevention and Treatment of the Vascular and Inflammatory Complications of Diabetes , 2000, Trends in Endocrinology & Metabolism.

[30]  A. Sobol,et al.  The role of platelets in diabetes-related vascular complications. , 2000, Diabetes research and clinical practice.

[31]  S. Hazen,et al.  Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. , 1999, The Journal of clinical investigation.

[32]  T. Yasuda,et al.  Increased serum levels of advanced glycation end-products and diabetic complications. , 1998, Diabetes research and clinical practice.

[33]  T. Watanabe,et al.  Increased aggregation of human platelets produced by advanced glycation end products in vitro. , 1998, Biochemical and biophysical research communications.

[34]  A. Schmidt,et al.  Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.

[35]  C. Watala,et al.  Decreased Platelet Membrane Fluidity Due to Glycation or Acetylation of Membrane Proteins , 1992, Thrombosis and Haemostasis.

[36]  P. Winocour.  Platelet Abnormalities in Diabetes Mellitus , 1992, Diabetes.

[37]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[38]  M. Suthanthiran,et al.  Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins , 1991, The Journal of experimental medicine.

[39]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[40]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. , 2013, European heart journal.

[41]  G. Lippi,et al.  The metabolic syndrome and the risk of arterial and venous thrombosis. , 2008, Thrombosis research.

[42]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[43]  T. Pietrucha,et al.  Membrane lipid fluidity of blood platelets: a common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood. , 1998, Platelets.